In China, how does FoundationONE NGS sequencing compare to common

In China, how does FoundationONE NGS sequencing compare to common "hotspot panels" with respect to detecting clinically actionable alterations?

In China, how does FoundationONE NGS sequencing compare to common “hotspot panels” with respect to detecting clinically actionable alterations? How does FoundationONE technology differ from “hotspot” panels?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Yilong Wu, MD

Yilong Wu, MD

Vice President
Guangdong General Hospital
Guangdong Academy of Medical Sciences
Director, Guangdong Lung Cancer Institute
Guangzhou, China